In line with above mentioned, recently approved therapies for unresectable HCC comprising atezolizumab and bevacizumab, inhibitors of PD-L1 and vascular endothelial growth factor (VEGF), showed better prognosis in HCC patients and were approved as the first-line therapy for unresectable HCC (9). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.